|
Takeshi Yoda
Department Kawasaki University of Medical Welfare , Position Associate Professor |
|
| Article types | 原著 |
| Language | English |
| Peer review | Peer reviewed |
| Title | Health state utilities of patients with hepatitis B and C and hepatitis-related conditions in Japan. |
| Journal | Formal name：Scientific reports Abbreviation：Sci Rep ISSN code：20452322/20452322 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 12(1),pp.17139 |
| Author and coauthor | Sugimori Hiroki, Hirao Maki, Igarashi Ataru, Yatsuhashi Hiroshi, Ikeda Shunya, Masaki Naohiko, Yotsuyanagi Hiroshi, Yoda Takeshi, Odajima Takeshi, Takura Tomoyuki, Hirao Tomohiro |
| Publication date | 2022/10 |
| Summary | Health state utilities are global measurements of quality of life and have been used to evaluate health outcomes for the cost-utility analysis. This study aimed to estimate the health state utilities of patients with hepatitis B (HB), hepatitis C (HC), and hepatitis-related diseases in Japan. We distributed a self-administered questionnaire, including the EuroQol 5-Dimension 5-Level (EQ-5D-5L), to 9,952 outpatients with several clinical conditions caused by HB or HC virus infection (such as asymptomatic chronic hepatitis, chronic hepatitis, compensated cirrhosis, and decompensated cirrhosis) and estimated the condition-specific utilities of patients with HB or HC. In patients with more severe conditions (patients with acute hepatitis, fulminant hepatitis, and hepatocellular carcinoma and patients undergoing post-liver transplantation), the utilities of these severe conditions were estimated by three hepatitis experts using the EQ-5D-5L. The means of the utilities for acute hepatitis, fulminant hepatitis, asymptomatic chronic hepatitis, chronic hepatitis, compensated cirrhosis, compensated cirrhosis, hepatocellular carcinoma stage I/II, hepatocellular carcinoma stage III/IV, and post-liver transplantation were 0.529, - 0.111, 0.904, 0.868, 0.845, 0.722, 0,675, 0,428, and 0.651 and 0.876, 0.821, 0.737, 0.671, 0.675, 0.428, and 0.651 in HB and HC, respectively. To the best of our knowledge, this is the first study that comprehensively assessed the health state utilities of patients with HB, HC and hepatitis-related conditions from a nationwide survey in Japan using the EQ-5D-5L. |
| DOI | 10.1038/s41598-022-21470-3 |
| PMID | 36229479 |